Drug Trial Radar · NCT05203939
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
22
Actual
Start
Jan 24, 2022
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- OcugenIndustry
- Sponsor type
- Industry
- First posted
- Jan 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.
Conditions
- Retinitis Pigmentosa
- Leber Congenital Amaurosis
Interventions
OCU400 Low DoseDrug
subretinal injection of up to 1.66×10E10 vg/mL
OCU400 Med DoseDrug
subretinal injection of up to 3.33×10E10 vg/mL
OCU400 High DoseDrug
subretinal injection of up to 1.66×10E11 vg/mL
OCU400 Second Eye DosingDrug
subretinal injection of 1.0x10E11vg/mL in 250 μl
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study Drug-related adverse events (SDAE)Time frame: 1 year
- Treatment-Emergent adverse events (TEAEs)Time frame: 1 year
- Serious adverse events (SAEs)Time frame: 1 year
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona
Ocugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute
La Jolla, California
Ocugen Site 3 - Bascom Palmer Eye Institute
Miami, Florida
Ocugen Site 6 - Emory University
Atlanta, Georgia
Ocugen Site 2 - Casey Eye Institute - OHSU
Portland, Oregon
Ocugen Site 8 - Mid Atlantic Retina - Wills Eye Hospital
Philadelphia, Pennsylvania
Ocugen Site 1 - Retina Foundation of the Southwest
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.